Serum levels of Lp(a) are related to waist circumference in NAFLD patients with low prevalence of co-morbidities

References

• Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013;273:6–30.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Hall JH. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60:716–21.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PBl. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46–57.
   PubMed Web of Science ®Google Scholar
• Seimon TA, Nadolsk MJi, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010;12:467–82.
   PubMed Web of Science ®Google Scholar
• Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005;80:219–30.
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, O’Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemicpatients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal AntibodyInhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013;128:962–9.
   PubMed Web of Science ®Google Scholar
• Corsetti JP, Sterry JA, Sparks JD, Sparks CE, Weintraub M. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem 1991;37:1191–95.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, Deluca C, White CC, Cupples LA, McNamara JR, Seman LJ, Bongard V, Schaefer EJ. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011;52:1181–7.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844–53.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Marcovina SM. Lipoprotein(a) metabolism. Curr Opin Lipidol 2014;25:189–93.
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama 2009;302:1993–2000.
   PubMed Web of Science ®Google Scholar
• Albers JJ, Slee A, O’Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerideand Impact on Global Health Outcomes). J Am Coll Cardiol 2013;62:1575–9.
   PubMed Web of Science ®Google Scholar
• Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial. Circulation 2014;129:635–42.
   PubMed Web of Science ®Google Scholar
• Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J; Emerging Risk Factors Collaboration. Lipid-related markers and cardiovascular disease prediction. Jama 2012;307:2499–506.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013;61:1146–56.
   PubMed Web of Science ®Google Scholar
• Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL, Rimm EB, Tsimikas S, Mukamal KJ. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 2013;61:2169–79.
   PubMed Web of Science ®Google Scholar
• Bea AM, Mateo-Gallego R, Jarauta E, Villa-Pobo R, Calmarza P, Lamiquiz-Moneo I, Cenarro A, Civeira F. Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia. Clin Investig Arterioscler 2014;26:176–83.
   PubMedGoogle Scholar
• Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, Retterstøl K. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis 2011;216:426–32.
   PubMed Web of Science ®Google Scholar
• Kolski B, Tsimika S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol 2012;23:560–8.
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Hamsten A, Veglia F, de Faire U, Humphries SE, Smit AJ, Giral P, Kurl S, Rauramaa R, Mannarino E, Grossi E, Paoletti R, Tremoli E, IMPROVE Study Group. Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. J Am Coll Cardiol 2012;60:1489–99.
   PubMed Web of Science ®Google Scholar
• Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M, Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Ikram MA, Völzke H, Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D, PROG-IMT study group. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol 2016;23:194–205.
   PubMed Web of Science ®Google Scholar
• Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001;34:583–8.
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Kaya H, Hergenç G. ‘Atherogenic index of plasma’ (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol 2010;4:89–98.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, Capone D, Pasanisi F. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond) 2009;6:6.
   PubMed Web of Science ®Google Scholar
• Hislop MS, St Clair Gibson A, Lambert MI, Noakes TD, Marais AD. Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis 2001;159:425–32.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.
   PubMed Web of Science ®Google Scholar
• Hattersley JG, Möhlig M, Roden M, Arafat AM, Loeffelholz CV, Nowotny P, Machann J, Hierholzer J, Osterhoff M, Khan M, Pfeiffer AF, Weickert MO. Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques. PLoS One 2012;7:e39029.
   PubMed Web of Science ®Google Scholar
• Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, Li RK, Zeng MS, Gao Xl. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring) 2012;20:444–52.
   PubMed Web of Science ®Google Scholar
• Stein J, Korcarz C, Hurst R, Lonn E, Kendall C, Mohler E, Najjar SS, Rembold CM, Post WS. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the american society of echocardiography carotid intima-media thickness task force. Endorsed by the society for vascular medicine. J Am Soc Echocardiogr 2008;21:93–111.
   PubMed Web of Science ®Google Scholar
• Saeedi R, Li M, Allard M, Frohlich J. Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. Clin Biochem 2014;47:1098–9.
   PubMed Web of Science ®Google Scholar
• Dobiásová M, Raslová K, Rauchová H, Vohnout B, Ptácková K, Frohlich J. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction. Physiol Res 2001;50:1–8.
   PubMed Web of Science ®Google Scholar
• Velmurugan K, Deepa R, Ravikumar R, Lawrence JB, Anshoo H, Senthilvelmurugan M, Enas EA, Mohan V. Relationship of lipoprotein(a) with intimal medial thickness of the carotid artery in Type 2 diabetic patients in south India. Diabet Med 2003;20:455–61.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Egusa G, Yamakido M. Carotid atherosclerosis and serum lipoprotein(a) concentrations in patients with NIDDM. Diabetes Care 1997;20:829–31.
   PubMed Web of Science ®Google Scholar
• Abdou AS, Magour GM, Mahmoud MM. Evaluation of some markers of subclinical atherosclerosis in Egyptian young adult males with abdominal obesity. Br J Biomed Sci 2009;66:143–7.
   PubMed Web of Science ®Google Scholar
• El-Gendi SS, Bakeet MY, El-Hamed EA, Ibrahim FK, Ahmed R. The value of lipoprotein (a), homocysteine, and Doppler of carotid and femoral arteries in assessment of atherosclerosis in asymptomatic cardiovascular risk patients. J Cardiol 2008;52: 202–11.
   PubMed Web of Science ®Google Scholar
• Lyons TJ, Jenkins AJ, Zheng D, Klein RL, Otvos JD, Yu Y, Lackland DT, McGee D, McHenry MB, Lopes-Virella M, Garvey WT, DCCT/EDIC Research Group. Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabetic Medicine 2006;23:955–66.
   PubMed Web of Science ®Google Scholar
• Srámek A, Reiber JH, Baak-Pablo R, Sturk A, Rosendaal FR. Lipoprotein(a) and ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery. J Thromb Haemost 2003;1:374–9.
   PubMed Web of Science ®Google Scholar
• Kotani K, Sakane N. Carotid intima-media thickness in asymptomatic subjects with low Lipoprotein(a) levels. J Clin Med Res 2012;4:130–4.
   PubMedGoogle Scholar
• Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357–65.
   PubMed Web of Science ®Google Scholar
• Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, Jacqueminet S, Giral P, Monneret D, Imbert-Bismut F, Ratziu V, Hartemann-Huertier A, Housset C, Poynard T, FLIP Consortium. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment Pharmacol Ther 2014;40:1081–93.
   PubMed Web of Science ®Google Scholar
• Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V, Bouillet B, Brindisi MC, Duvillard L, Hillon P, Cercueil JP, Verges B. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 2009;94:4103–6.
   PubMed Web of Science ®Google Scholar
• Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009;204:521–5.
   PubMed Web of Science ®Google Scholar
• Borruel S, Moltó JF, Alpañés M, Fernández-Durán E, Álvarez-Blasco F, Luque-Ramírez M, Escobar-Morreale HFl. Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index. PLoS One 2014;9:e114112.
   PubMed Web of Science ®Google Scholar
• Hermsdorff HH, Barbosa KB, Volp AC, Puchau B, Bressan J, Zulet MÁ, Martínez JA. Gender-specific relationships between plasma oxidized low-density lipoprotein cholesterol, total antioxidant capacity, and central adiposity indicators. Eur J Prev Cardiol 2014;21:884–91.
   PubMed Web of Science ®Google Scholar
• Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Isenovic ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci 2015;52:70–85.
   PubMed Web of Science ®Google Scholar
• Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, Newell-Morris L, Shofer JB, Wahl PW. Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999;22:1808–12.
   PubMed Web of Science ®Google Scholar
• Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2013;21:E439–47.
   PubMed Web of Science ®Google Scholar
• Armellini F, Zamboni M, Rigo L, Bergamo-Andreis IA, Robbi R, De Marchi M, Bosello O. Sonography detection of small intra-abdominal fat variations. Int J Obes 1991;15:847–52.
   PubMed Web of Science ®Google Scholar
• Akaike M, Azuma H, Kagawa A, Matsumoto K, Hayashi I, Tamura K, Nishiuchi T, Iuchi T, Takamori N, Aihara K, Yoshida T, Kanagawa Y, Matsumoto T. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002;48:1454–9.
   PubMed Web of Science ®Google Scholar
• Claridge MW, Bate GR, Hoskins PR, Adam DJ, Bradbury AW, Wilmink AB. Measurement of arterial stiffness in subjects with vascular disease: are vessel wall changes more sensitive than increase in intima-media thickness? Atherosclerosis 2009;205:477–80.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guallar E, Qiao Y, Wasserman BA. Is carotid intima-media thickness as predictive as other noninvasive techniques for the detection of coronary artery disease? Arterioscler Thromb Vasc Biol 2014;34:1341–5.
   PubMed Web of Science ®Google Scholar
• Hoenig MR, Cowin G, Buckley R, McHenery C, Coulthard A. Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: a magnetic resonance imaging study. Lipids Health Dis 2011;10:12.
   PubMed Web of Science ®Google Scholar
• Bos S, Duvekot MH, Touw-Blommesteijn AC, Verhoeven AJ, Mulder MT, Watts GF, Sijbrands EJ, Roeter van Lennep JE. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2015;242:226–9.
   PubMed Web of Science ®Google Scholar
• Calmarza P, Trejo JM, Lapresta C, Lopez P. Lack of association between carotid intima-media thickness and apolipoprotein (a) isoforms in a sample of Spanish general population. J Cardiol 2013;61:372–7.
   PubMed Web of Science ®Google Scholar